Mutant MMLV Reverse Transcriptase for High GC Content cDNA Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Reverse transcriptases face challenges in efficiently synthesizing full-length cDNA from RNA templates, particularly those with high GC content, due to RNA secondary structure formation, which can lead to truncated products and reduced enzyme activity at elevated temperatures.
Innovation Solution
A mutant Moloney murine leukemia virus (MMLV) reverse transcriptase with specific amino acid substitutions and an optional C-terminal sequence is used, which maintains or enhances reverse transcriptase activity and RNAseH activity, allowing for increased full-length cDNA production, especially at temperatures above 42°C, even with high GC content templates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If the temperature is increased to reduce RNA secondary structure formation, then reverse transcriptase fidelity and cDNA length are improved, but RNA integrity is compromised due to lower enzyme activity
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of reverse transcriptase (specifically substitutions at positions 13, 18, 55, 67, 78, 98, and 107) to alter the enzyme's thermal stability and catalytic properties. These parameter changes enable the enzyme to maintain high activity at elevated temperatures (50-65°C) while preserving fidelity, thus resolving the contradiction between temperature-dependent fidelity and temperature-dependent activity.
2Length of moving object
If the temperature is increased to prevent RNA secondary structure formation, then full-length cDNA synthesis is improved, but enzyme activity decreases
Solution Approach 1:
The patent modifies enzyme parameters through specific amino acid substitutions that enhance thermostability without compromising catalytic function. This allows the enzyme to operate effectively at higher temperatures where RNA secondary structures are minimized, thereby achieving full-length cDNA synthesis while maintaining sufficient enzyme activity.
3Ease of manufacture
If standard MMLV reverse transcriptase is used, then the enzyme is readily available, but it produces truncated cDNA molecules due to stalling at RNA secondary structures
Solution Approach 1:
The patent creates modified versions of MMLV reverse transcriptase with specific amino acid substitutions that enhance the enzyme's ability to traverse RNA secondary structures. These parameter changes improve processivity and reduce stalling, resulting in full-length cDNA products while maintaining the benefit of using MMLV-based enzymes.
Solution Approach 2:
The patent combines elements from different reverse transcriptase variants and incorporates specific mutations known to improve processivity and thermostability. This composite approach creates an optimized enzyme that overcomes the limitations of standard MMLV reverse transcriptase while retaining its availability and ease of use.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mutant MMLV reverse transcriptase significantly increases the proportion of full-length cDNA molecules, improving synthesis efficiency and fidelity compared to commercially available variants, particularly for GC-rich templates, by optimizing enzyme performance at higher temperatures.
Implementation Method 1
reverse transcriptases were first identified in RNA viruses. Subsequently, reverse transcriptases were isolated and purified directly from virus particles, cells or tissues
Implementation Method 2
an RNaseH activity that catalyzes the cleavage of RNA in RNA-DNA hybrids
Implementation Method 3
The formation of secondary structure can be avoided at higher temperature. While this also reduces non-specific priming and thereby increases reverse transcriptase fidelity
Data Source
AI summary
A mutant MMLV reverse transcriptase that may have an improvement in one or more properties is provided. For example, the present reverse transcriptase is believed to be more efficient relative to other commercially available MMLV reverse transcriptase variants, particularly for templates with a higher GC content.